Genenta Science Amends ATM Sales Agreement
Ticker: GNTA · Form: 6-K · Filed: Dec 20, 2024 · CIK: 1838716
| Field | Detail |
|---|---|
| Company | Genenta Science S.P.A. (GNTA) |
| Form Type | 6-K |
| Filed Date | Dec 20, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $303,001, $29,696,999, $16,059,815, $13,637,184 |
| Sentiment | neutral |
Sentiment: neutral
Topics: atm-offering, amendment, filing
TL;DR
Genenta amended its ATM sales agreement on 12/20/24, filed under F-3.
AI Summary
On December 20, 2024, Genenta Science S.p.A. amended its At-the-Market (ATM) Sales Agreement. This amendment is incorporated by reference into the company's Form F-3 registration statement (File No. 333-271901).
Why It Matters
This amendment to the ATM sales agreement could impact the company's ability to raise capital through the sale of its common stock in the public market.
Risk Assessment
Risk Level: low — The filing is a routine amendment to an existing sales agreement and does not appear to introduce new material risks.
Key Players & Entities
- Genenta Science S.p.A. (company) — Registrant
- December 20, 2024 (date) — Date of ATM Sales Agreement Amendment
- 333-271901 (document_id) — Form F-3 Registration Statement File Number
FAQ
What specific changes were made to the ATM Sales Agreement?
The filing states that the ATM Sales Agreement was amended on December 20, 2024, but does not provide the specific details of the amendments within this Form 6-K.
What is the purpose of incorporating this Form 6-K into the Form F-3 registration statement?
Incorporating the Form 6-K into the Form F-3 allows the company to update or supplement information related to its securities offerings under the registration statement.
When was the original ATM Sales Agreement entered into?
The filing does not specify the date the original ATM Sales Agreement was entered into, only that it was amended on December 20, 2024.
What is the file number for the Form F-3 registration statement?
The file number for the Form F-3 registration statement is 333-271901.
Is Genenta Science S.p.A. an Italian company?
Yes, the filing indicates that Genenta Science S.p.A. has its principal executive offices in Milan, Italy.
Filing Stats: 818 words · 3 min read · ~3 pages · Grade level 12 · Accepted 2024-12-20 16:27:16
Key Financial Figures
- $303,001 — ospectus”), for gross proceeds of $303,001 under the Original Sales Agreement. The
- $29,696,999 — sold pursuant to the Sales Agreement to $29,696,999, which consists of $16,059,815 remainin
- $16,059,815 — ement to $29,696,999, which consists of $16,059,815 remaining as originally authorized unde
- $13,637,184 — prospectus supplement and an additional $13,637,184, and (ii) replacing Capital One with Ro
Filing Documents
- form6-k.htm (6-K) — 26KB
- ex1-1.htm (EX-1.01) — 55KB
- ex5-1.htm (EX-5.1) — 61KB
- ex10-1.htm (EX-10.1) — 1KB
- ex5-1_001.jpg (GRAPHIC) — 8KB
- ex5-1_002.jpg (GRAPHIC) — 41KB
- ex10-1_001.jpg (GRAPHIC) — 1126KB
- 0001493152-24-051070.txt ( ) — 1762KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENENTA SCIENCE S.P.A. By: /s/ Richard B. Slansky Name: Richard B. Slansky Title: Chief Financial Officer Dated: December 20, 2024